| PPARG and KAT5 |
peroxisome proliferator-activated receptor gamma |
K(lysine) acetyltransferase 5 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Chromatin modifying enzymes
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- formation of the beta-catenin:TCF transactivating complex
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by Wnt
- Signaling by WNT in cancer
- HATs acetylate histones
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and RB1 |
peroxisome proliferator-activated receptor gamma |
retinoblastoma 1 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- E2F mediated regulation of DNA replication
- DNA Damage/Telomere Stress Induced Senescence
- Synthesis of DNA
- Mitotic Prophase
- Cellular Senescence
- G1 Phase
- Regulation of DNA replication
- Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
- Orc1 removal from chromatin
- S Phase
- Cyclin E associated events during G1/S transition
- Cell Cycle, Mitotic
- M Phase
- Orc1 removal from chromatin
- Cyclin D associated events in G1
- Formation of Senescence-Associated Heterochromatin Foci (SAHF)
- G1/S Transition
- Removal of licensing factors from origins
- Cyclin A:Cdk2-associated events at S phase entry
- Switching of origins to a post-replicative state
- Mitotic G1-G1/S phases
- Condensation of Prophase Chromosomes
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and ZBTB9 |
peroxisome proliferator-activated receptor gamma |
zinc finger and BTB domain containing 9 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and NSD1 |
peroxisome proliferator-activated receptor gamma |
nuclear receptor binding SET domain protein 1 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Chromatin modifying enzymes
- Chromatin organization
- PKMTs methylate histone lysines
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and RELA |
peroxisome proliferator-activated receptor gamma |
v-rel avian reticuloendotheliosis viral oncogene homolog A |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Signaling by the B Cell Receptor (BCR)
- NF-kB is activated and signals survival
- Downstream TCR signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Cellular Senescence
- RIP-mediated NFkB activation via ZBP1
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Downstream signaling events of B Cell Receptor (BCR)
- Toll Like Receptor TLR1:TLR2 Cascade
- Activated TLR4 signalling
- FCERI mediated NF-kB activation
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- ZBP1(DAI) mediated induction of type I IFNs
- p75NTR signals via NF-kB
- Transcriptional regulation of white adipocyte differentiation
- MyD88 dependent cascade initiated on endosome
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
- Regulated proteolysis of p75NTR
- Signalling by NGF
- TRIF-mediated TLR3/TLR4 signaling
- Cytosolic sensors of pathogen-associated DNA
- Senescence-Associated Secretory Phenotype (SASP)
- Cytokine Signaling in Immune system
- p75 NTR receptor-mediated signalling
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- TCR signaling
- Signaling by Interleukins
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Activation of NF-kappaB in B cells
- Interleukin-1 processing
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Fc epsilon receptor (FCERI) signaling
- TRAF6 mediated NF-kB activation
- Adaptive Immune System
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and CHD7 |
peroxisome proliferator-activated receptor gamma |
chromodomain helicase DNA binding protein 7 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and MED1 |
peroxisome proliferator-activated receptor gamma |
mediator complex subunit 1 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- PPARA activates gene expression
- Organelle biogenesis and maintenance
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Nuclear Receptor transcription pathway
- REV-ERBA represses gene expression
- RORA activates circadian gene expression
- Mitochondrial biogenesis
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- Activation of gene expression by SREBF (SREBP)
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Transcriptional activation of mitochondrial biogenesis
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- Orphan transporters
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and LMO4 |
peroxisome proliferator-activated receptor gamma |
LIM domain only 4 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and ZNF496 |
peroxisome proliferator-activated receptor gamma |
zinc finger protein 496 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Generic Transcription Pathway
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and TFAP2A |
peroxisome proliferator-activated receptor gamma |
transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and JMJD1C |
peroxisome proliferator-activated receptor gamma |
jumonji domain containing 1C |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Factors involved in megakaryocyte development and platelet production
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and PPM1B |
peroxisome proliferator-activated receptor gamma |
protein phosphatase, Mg2+/Mn2+ dependent, 1B |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- ISG15 antiviral mechanism
- Interferon Signaling
- Cytokine Signaling in Immune system
- Antiviral mechanism by IFN-stimulated genes
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and RANBP9 |
peroxisome proliferator-activated receptor gamma |
RAN binding protein 9 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Axon guidance
- L1CAM interactions
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and GRIP1 |
peroxisome proliferator-activated receptor gamma |
glutamate receptor interacting protein 1 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Trafficking of GluR2-containing AMPA receptors
- Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
- Trafficking of AMPA receptors
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Transmission across Chemical Synapses
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and NFE2L3 |
peroxisome proliferator-activated receptor gamma |
nuclear factor, erythroid 2-like 3 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and NCOR1 |
peroxisome proliferator-activated receptor gamma |
nuclear receptor corepressor 1 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Loss of Function of TGFBR2 in Cancer
- PPARA activates gene expression
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Organelle biogenesis and maintenance
- Metabolism of lipids and lipoproteins
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- RORA activates circadian gene expression
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- Signaling by NOTCH1
- Transcriptional regulation of white adipocyte differentiation
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- Fatty acid, triacylglycerol, and ketone body metabolism
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Chromatin organization
- HDACs deacetylate histones
- Loss of Function of SMAD2/3 in Cancer
- Signaling by NOTCH
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- REV-ERBA represses gene expression
- Signaling by ERBB4
- Loss of Function of TGFBR1 in Cancer
- Mitochondrial biogenesis
- NOTCH1 Intracellular Domain Regulates Transcription
- Nuclear signaling by ERBB4
- Chromatin modifying enzymes
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Transcriptional activation of mitochondrial biogenesis
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- SMAD4 MH2 Domain Mutants in Cancer
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and NCOR2 |
peroxisome proliferator-activated receptor gamma |
nuclear receptor corepressor 2 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Loss of Function of TGFBR2 in Cancer
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Metabolism of lipids and lipoproteins
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- Signaling by NOTCH1
- Transcriptional regulation of white adipocyte differentiation
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- Fatty acid, triacylglycerol, and ketone body metabolism
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Chromatin organization
- HDACs deacetylate histones
- Loss of Function of SMAD2/3 in Cancer
- Signaling by NOTCH
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- NOTCH1 Intracellular Domain Regulates Transcription
- Chromatin modifying enzymes
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- SMAD4 MH2 Domain Mutants in Cancer
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and FHOD1 |
peroxisome proliferator-activated receptor gamma |
formin homology 2 domain containing 1 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and ANP32A |
peroxisome proliferator-activated receptor gamma |
acidic (leucine-rich) nuclear phosphoprotein 32 family, member A |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- Regulation of mRNA stability by proteins that bind AU-rich elements
- HuR stabilizes mRNA
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|
| PPARG and HELZ2 |
peroxisome proliferator-activated receptor gamma |
helicase with zinc finger 2, transcriptional coactivator |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
- PPARA activates gene expression
- Organelle biogenesis and maintenance
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- REV-ERBA represses gene expression
- RORA activates circadian gene expression
- Mitochondrial biogenesis
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- Activation of gene expression by SREBF (SREBP)
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Transcriptional activation of mitochondrial biogenesis
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- Orphan transporters
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
|